Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 119

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 119
---
 —       
  Foster, Genevieve        —            4,956       4,956      12,500  
  Gagnon, Gilles           41,962           —           —      12,250  
  Gerlach, Matthias        —              950         950      —       
  Ammer, Nicola            —            1,000       1,000      —       
  Teifel, Michael          —              500         500      —       
  La Fratta, Giuliano      —              500         333      —       
  Total                    46,207      43,424      43,257      64,500  

* Less than 1%

  (1)      Based on 3,123,513 Common Shares outstanding as at March 26, 2025                                  
  (2)      For information regarding option expiration dates and exercise price refer to the tables included  

  Item 7.      Major Shareholders and Related Party Transactions  
 ──────────────────────────────────────────────────────────────────

  Major shareholders  
 ──────────────────────

We are not directly or indirectly owned or controlled
by another corporation or by any foreign government. Based on filings with the SEC and the Canadian securities regulatory authorities,
as at March 26, 2025, no individual or entity, other than as set out below, beneficially owned, directly or indirectly, or exercised
control or direction over our Common Shares carrying more than 5% of the voting rights attached to all our Common Shares (to whom we
refer as our major shareholders).

Changes in Percentage Ownership by Major Shareholders

On July 1, 2020, Intracoastal Capital LLC became
a major shareholder due to the acquisition of over 5% of our outstanding Common Shares, but as of December 31, 2021 ceased to beneficially
own more than 5% of our Common Shares, based solely on a Schedule 13G filed with the SEC on February 11, 2022. On July 2, 2020, Lind
Global Macro Fund, LP became a major shareholder due to the acquisition of over 5% of our outstanding Common Shares, but as of December
31, 2021 ceased to beneficially own more than 5% of our Common Shares, based solely on a Schedule 13G filed with the SEC on February
11, 2022. As of the close of business on June